Mercado mundial de la medicina genómica: tendencias de la industria y pronóstico hasta 2029

Análisis y tamaño del mercado de la medicina genómica

Los medicamentos que se crean específicamente a partir de datos genéticos del ADN, el perfil de proteínas y su funcionalidad, al tiempo que se comprende cómo interactúan con la salud humana, se conocen como medicamentos genómicos, también conocidos como medicamentos personales. Estos medicamentos pueden revelar detalles específicos sobre los datos biológicos habituales de una persona, que luego pueden usarse para diseñar el régimen de tratamiento y los medicamentos adecuados para el paciente.

Data Bridge Market Research analiza que el mercado de la medicina genómica, que fue de USD 23.08 mil millones en 2021, se disparará hasta USD 75.67 mil millones para 2029, y se espera que experimente una CAGR del 16,00% durante el período de pronóstico de 2022 a 2029. Además de los conocimientos del mercado, como el valor de mercado, la tasa de crecimiento, los segmentos del mercado, la cobertura geográfica, los actores del mercado y el escenario del mercado, el informe de mercado curado por el equipo de Data Bridge Market Research también incluye un análisis experto en profundidad, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Alcance y segmentación del mercado de la medicina genómica      

Definición de mercado

The branch of science known as genomic medicine examines our DNA and how it interacts with our health using genomic data. They are able to gather information about a person's usual biological characteristics and use it to provide successful treatment.

Genomic Medicine Market Dynamics

Drivers

• Technological Advancements

Technology advancements and the potential for further research into the identification and monitoring of other biomarkers that may potentially be utilised for pharmacogenomics are other factors supporting the expansion of the global market for genomic medicine during the next five years.

• Rise in government spending on medicines

Growing government spending on precision medicine is anticipated to fuel industry expansion. The market for genomic medicine will grow faster from 2022 to 2029 due to other factors such as expanding genomic application areas, growing numbers of genomics projects, and rising demand for enhanced sequencing in cancer, pharmacogenomics, and rare condition detection.

• Rise in pharmaceuticals

The global market for genomic medicines will rise over the next five years due to rising research and advancements in the pharmaceutical business. The expansion of the worldwide market for genomic medicine in the ensuing five years will also be supported by growing government initiatives, individual investments, and an increase in the uses of genomic studies in the healthcare industry.

Opportunities

• Increase in the number of research and development activities 

The market's growth is fuelled by an increasing scientific research on genomic medicine. This will provide beneficial opportunities for the market growth.

Restraints/Challenges

The lack of adoption of genomic medicine, the instability of the regulatory environment, and the lack of provider awareness will restrain market expansion.

This genomic medicine market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the genomic medicine market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Genomic Medicine Market

The COVID-19 pandemic has considerably impacted the global market for genomic medicine in 2020. The COVID-19 outbreak has impacted various factors, including aircraft cancellations, quarantines, travel prohibitions, restaurant closures, and restrictions on all indoor and outdoor events. More than fifty nations declared lockdown and a health emergency resulted in a sharp decline in business confidence, escalating public panic, and future uncertainty.

Global Genomic Medicine Market Scope

The genomic medicine market is segmented on the basis of application and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Application

• Oncology
• Cardiology
• Paediatrics
• Endocrinology
• Respiratory Medicine
• Rare Genetic Disorders
• Infectious Diseases
• Others

End- User

• Hospitals
• Clinics
• Academic Institutions
• Research Institutions

Genomic Medicine Market Regional Analysis/Insights

The genomic medicine market is analysed and market size insights and trends are provided by country, application and end-user as referenced above.

The countries covered in the genomic medicine market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the genomic medicine market due to increasing R&D in the genomic medicine and availability of various universities offering education programs on genomic medicine.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the rising health awareness among the people and growing demand of advanced medical technology.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Genomic Medicine Market Share Analysis

El panorama competitivo del mercado de la medicina genómica proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia global, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, la amplitud y la variedad de productos, y el dominio de las aplicaciones. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas en relación con el mercado de la medicina genómica.

Algunos de los principales actores que operan en el mercado de la medicina genómica son:

• Genome Medical, Inc. (Estados Unidos)
• BioMed Central Ltd (Reino Unido)
• Aevi Genomic Medicine, Inc. (Israel)
• Congenica Ltd. (Reino Unido)
• Deep Genomics (Canadá)
• Medicina Editas (Estados Unidos)
• Clínica Cleveland (Estados Unidos)
• Illumina, Inc. (Estados Unidos)
• Thermo Fisher Scientific (Estados Unidos)
• QIAGEN NV (Países Bajos)
• Agilent Technologies, Inc. (Estados Unidos)
• Laboratorios Bio-Rad, Inc. (Estados Unidos)
• F. Hoffmann-La Roche Ltd. (Suiza)
• BGI (China)

SKU-52824